HTGM
HTG Molecular Diagnostics Inc
-37.26%
$4.67 - $2.93
Feb 7th 2023 - Mar 21st 2023
Jan, 23, 2023
Micro float (~600K), great company with increase i... See more
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K flo... See more
SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Jan, 11, 2023
$SAVA Love this, sold at 62 a few weeks ago, bough... See more
Nov, 29, 2022
Good company statement and analyst upgrade.
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Dec, 30, 2022
The analyst comments "TGTX stock is up >15... See more
Dec, 30, 2022
Ignorant analyst are a plus.
Jan, 23, 2023
Micro float (~600K), great company with increase in YoY revenue, and high analyst price targets.
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K float 500%+ Cost to Borrow $3M MC w/ $14M in cash Recent analyst targets of $15.00+ Excellent technical setup Also watching: $WISA $SLRX $GNUS
Jan, 11, 2023
$SAVA Love this, sold at 62 a few weeks ago, bought back rince and repeat.. $aehl very bullish uptrend Marketwatch analyst BUY with PT of 16+ and love $GREE
Nov, 29, 2022
Good company statement and analyst upgrade.
Nov, 13, 2022
$QQQ $SOS $SNAP $SNDL $SAVA Top analyst price target for next week~~ amazing-room.stockmarketus.net/
Nov, 9, 2022
Bernardino is a 5-star analyst with an average return of 19.9% and a 32.4% success rate.
Dec, 30, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Dec, 30, 2022
Ignorant analyst are a plus.
Dec, 30, 2022
This stock would go far beyond analysts Price Target.
Dec, 30, 2022
$TGTX , absolutely amazing….Scumbag’s Bank of America analyst rated TG today as underperform $6….total joke….I guess the analyst is waiting for FDA approval…LOL ….stick to loans and mortgages….very bullish TG community Longs….
Dec, 29, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,